Article

Lab study supports longitudinal venting slit modification to Baerveldt tube shunt

Author(s):

Richmond, CA-When implanting the B?r-veldt non-valved glaucoma tube shunt (Advanced Medical Optics), placement of a 1.2-mm longitudinal venting slit in a totally occluded tube appears to be a safe and effective modification for achieving an acceptable IOP and minimizing the risk of hypotony in the early postoperative period, said David Gilbert, MD, a glaucoma specialist in private practice with Kaiser Permanente here.

While a resident in the Department of Ophthalmology at Wake Forest University Baptist Medical Center, Winston-Salem, NC, Dr. Gilbert and Brent Bond, MD, assistant professor of ophthalmology, performed a study in an in vitro model to assess the effects of various techniques for avoiding early postoperative hypotony. They compared results achieved with placement of the venting slit against two other modifications: partial occlusion of the tube with a 3-0 suture (Supramid, S. Jackson Inc.) and total occlusion of the tube lumen followed by perforation with a 27-gauge needle. Only the venting slit method was associated with an acceptable IOP.

Clinical study needed

Variability exists among surgeons with regard to the modification technique for preventing early postoperative hypotony, he said. In the absence of solid data to support any particular technique, selection of the various options is based primarily on surgeon preference.

To gain better insight into the issue, Drs. Gilbert and Bond devised a testing apparatus to measure intraluminal pressure while Baerveldt tube shunts mounted on cadaver eyes were infused with balanced salt solution at a physiological flow rate (2 μl/min). The shunts were positioned 10 mm posterior to the limbus and secured with a 10-0 nylon suture. To occlude the shunts, a 4-0 nylon intraluminal stent suture was placed and ligated watertight with a 6-0 suture (Vicryl, Ethicon).

Each of the three tube modifications was studied in three eyes. The mean (range) IOP results were 2 mm Hg (1.6 to 2.8) for the 3-0 suture, 5.9 mm Hg (4.6 to 8.2) for the 27-gauge perforation, and 14.8 mm Hg (12.6 to 17.3) for the 1.2-mm venting slit.

In a previous experiment using the same model, Dr. Gilbert and colleagues compared the effects of varying the length of the venting slit on intraluminal IOP. In that study, they investigated three different length slits: 0.5, 1, and 1.5 mm.

"Based on the results from that investigation, we felt the best length was somewhere between 1 and 1.5 mm, so we chose a 1.2-mm venting slit for the follow-up study comparing the different techniques," he said.

Long term IOP control

Over the longer term, IOP control is regulated by the device itself, Dr. Gilbert noted, because the occlusion suture is reabsorbed and the tube shunt provides the outflow resistance once the plate becomes encapsulated.

"Some modification is needed to bridge the gap between when the device is first implanted and the few weeks it takes for suture reabsorption," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.